Xeris Biopharma Holdings (XERS) EBIT: 2020-2025
Historic EBIT for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $6.7 million.
- Xeris Biopharma Holdings' EBIT rose 152.21% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year increase of 121.70%. This contributed to the annual value of -$33.6 million for FY2024, which is 23.55% up from last year.
- Latest data reveals that Xeris Biopharma Holdings reported EBIT of $6.7 million as of Q3 2025, which was up 50.18% from $4.5 million recorded in Q2 2025.
- In the past 5 years, Xeris Biopharma Holdings' EBIT ranged from a high of $6.7 million in Q3 2025 and a low of -$48.3 million during Q4 2021.
- In the last 3 years, Xeris Biopharma Holdings' EBIT had a median value of -$8.2 million in 2024 and averaged -$6.3 million.
- As far as peak fluctuations go, Xeris Biopharma Holdings' EBIT slumped by 162.43% in 2024, and later skyrocketed by 154.75% in 2025.
- Quarterly analysis of 5 years shows Xeris Biopharma Holdings' EBIT stood at -$48.3 million in 2021, then surged by 68.57% to -$15.2 million in 2022, then spiked by 35.13% to -$9.8 million in 2023, then soared by 117.06% to $1.7 million in 2024, then soared by 152.21% to $6.7 million in 2025.
- Its last three reported values are $6.7 million in Q3 2025, $4.5 million for Q2 2025, and -$3.1 million during Q1 2025.